J Cancer 2014; 5(9):765-773. doi:10.7150/jca.10471 This issue


Interleukin-7 and Interleukin-15 for Cancer

Paul Zarogoulidis1✉, Sofia Lampaki1, Lonny Yarmus2, Ioannis Kioumis1, Georgia Pitsiou1, Nikolaos Katsikogiannis3, Wolfgang Hohenforst-Schmidt4, Qiang Li5, Haidong Huang5, Antonios Sakkas6, John Organtzis1, Leonidas Sakkas6, Ioannis Mpoukovinas7, Kosmas Tsakiridis8, George Lazaridis9, Konstantinos Syrigos10, Konstantinos Zarogoulidis1

1. Pulmonary Department-Oncology Unit, ``G. Papanikolaou`` General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
2. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, U.S.A.
3. Surgery Department (NHS), University General Hospital of Alexandroupolis, Alexandroupolis, Greece.
4. II Medical Clinic, ``Coburg`` Hospital, University of Wuerzburg, Coburg, Germany.
5. Department of Respiratory Diseases, Changhai Hospital/First Affiliated Hospital of the Second Military Medical University, Shanghai, China.
6. Pathology Department, ``G. Papanikolaou`` General Hospital, Thessaloniki, Greece.
7. Oncology Department, ``BioMedicine`` Private Hospital, Thessaloniki, Greece.
8. Cardiothoracic Surgery Department, ``Saint Luke`` Private Hospital, Thessaloniki, Greece.
9. Oncology Department, ``G. Papageorgiou`` University Hospital, Thessaloniki, Greece.
10. Oncology Department, ``Sotiria`` Hospital, University of Athens, Athens, Greece.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Zarogoulidis P, Lampaki S, Yarmus L, Kioumis I, Pitsiou G, Katsikogiannis N, Hohenforst-Schmidt W, Li Q, Huang H, Sakkas A, Organtzis J, Sakkas L, Mpoukovinas I, Tsakiridis K, Lazaridis G, Syrigos K, Zarogoulidis K. Interleukin-7 and Interleukin-15 for Cancer. J Cancer 2014; 5(9):765-773. doi:10.7150/jca.10471. Available from https://www.jcancer.org/v05p0765.htm

File import instruction


Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

Keywords: IL-7, IL-15, Cancer, Imunomodulation.